Abstract: A method is provided for distinguishing between and/or diagnosing Parkinson's disease (PD) or multiple system atrophy (MSA) in a subject who is exhibiting symptoms associated with both PD and MSA. The method comprises: (A) contacting a biological sample obtained from the subject and comprising soluble, misfolded alpha-synuclein (?S) protein with a pre-incubation mixture comprising a monomeric ?S substrate and an indicator to form an incubation mixture; (B) conducting an incubation cycle two or more times on the incubation mixture to form misfolded ?S aggregates; (C) subjecting the incubation mixture to excitation and detecting via indicator fluorescence emission the misfolded ?S aggregates; and (D) diagnosing the subject has having PD or MSA depending on the fluorescence emission intensity. In some aspects, the incubation cycles are conducted in the presence of a bead.

Abstract: Previous electrochemically-powered yarn muscles cannot be usefully operated between extreme negative and extreme positive potentials, since strokes during electron injection and during hole injection partially cancel because they are in the same direction. Unipolar-stroke carbon nanotube yarn muscles are described in which muscle strokes are additive between extreme negative and extreme positive potentials, and stroke increases with potential scan rate. These electrochemical artificial muscles include an electrically conducting twisted or coiled yarn and a material that dramatically shifts the potential of zero charge of the electrochemically actuated yarn.

Abstract: Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

Abstract: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.

Abstract: A method and device for isolating a migratory cell population from a mixed population of migratory cells and non-migratory cells is described herein. The method comprises placing the mixed population of migratory cells and non-migratory cells in contact with a device having one or more microchannels; and isolating the migratory cell population within the microchannels following an incubation period, wherein the one or more microchannels have an average size in a proliferation direction of the migratory cells that is less than a minimum proliferation space of the migratory cells along the proliferation direction.

Abstract: The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally-transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.

Abstract: The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.

Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.

Abstract: Provided is a method of making a preliposomal Annamycin lyophilizate, the composition made by the method, and the use of the composition made thereby in the treatment of cancer.

Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Abstract: The present techniques may provide improved processing and functionality of performance of the 128-bit AES Algorithm, which may provide improved power consumption. For example, in an embodiment, an encryption and decryption apparatus may comprise memory storing a current state matrix of an encryption or decryption process and a plurality of multiplexers configured to receive from the memory current elements of the state matrix stored in the memory, perform a cyclic shift on the received elements of the state matrix, and transmit the shifted elements to the memory for storage as a new state matrix.

Abstract: A method of manufacturing an electrical device, comprising: forming a patterned inorganic liftoff layer to expose a target electrode site on a softening polymer layer, depositing an electrode layer on the inorganic liftoff layer and on the exposed target electrode site, and removing the inorganic liftoff layer by a horizontal liftoff etch to leave the electrode layer on the exposed target electrode site.

Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

Abstract: Systems, methods, and techniques are described herein for characterizing well treatment fluids and well treatment fluid performance. For example, well treatment fluids can be characterized using microfluidic chips to determine fluid properties, with very small amounts of fluid used for the characterization process. Optical analysis and electrical conductivity analysis of well treatment fluids as they pass through different microfluidic pathways with different cross-sectional dimensions can be used to gain information about the well treatment fluid's composition, structure, and performance. In some cases, microfluidic pathways can be functionalized as a model for a wellbore and a reservoir (e.g., rock in the reservoir) to evaluate the performance of well treatment fluids by imaging the well treatment fluid as it flows into or through the functionalized model. These systems, methods, and techniques can allow for optimization of well treatment fluids prior to or during drilling or completion operations.

Abstract: Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2?.

Abstract: Provided herein are T cells expressing a chimeric antigen receptor (CAR) targeted to B cell activating factor receptor (BAFF-R). The CAR targeted to BAFF-R (BAFF-R CAR) described herein includes a domain that binds BAFF-R. Methods of making and using the BAFF-R CAR are also provided.

Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: A method of measuring fluid flow rate is provided. The method comprises positioning a piezoelectric sensor in a fluid flow stream and measuring a voltage output from the piezoelectric sensor caused by mechanical stress from the fluid flow stream. A fluid flow rate is calculated based on the measured voltage output according to predefined relationships between the voltage output and a number physical parameters.

Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

Abstract: Mid-IR light emitting diodes (LEDs) based on type-II quantum dot (QD) active regions grown with monolithically integrated semiconductor metal layers are provided. These LEDs comprise layers of type-II semiconductor (e.g., InGaSb) quantum dots integrated into a pn junction diode (e.g., InAs) grown above a highly doped backplane, such as an n++ InAs backplane, all in the same epitaxial growth. Aspects described herein minimize non-radiate recombination times and significantly increase radiative recombination rates by controlling the emission of the emitting QDs in the near field of an optical metal.